Clinical Manifestations and Management of Terbinafine-Induced Acute Generalized Exanthematous Pustulosis

Table 2

Clinical features, laboratory tests, and skin biopsies of 32 patients with terbinafine-induced acute generalized exanthematous pustulosis.

Parameters		Values
Clinical features	Nonfollicular pustules	31(96.9%)
	Erythematous plaques	27 (84.4%)
	Rash1	16 (50.0%)
	Pruritic	8 (25.0%)
	Pain	3 (9.4%)
	Edema	3 (9.4%)
	Targetoid lesion	2 (6.3%)
	Burning sensation	2 (6.3%)
	Chills	2 (6.3%)
	Mucosal involvement	4 (12.5%)
	Desquamation	10 (31.3%)
Fever (20)^a	>38°C	19 (59.4%)
	37.6°C	1 (3.1%)
Location	Trunk	14 (43.8%)
	Entire body	11 (34.4%)
	Extremities	17 (53.1%)
	Abdomen	4 (12.5%)
	Inguinal areas	8 (25.0%)
	Back	5 (15.6%)
	Thighs	4 (12.5%)
	Chest	3 (9.4%)
	Axilla	3 (9.4%)
	Buttocks	3 (9.4%)
	Neck	2 (6.3%)
	Facial involvement	2 (6.3%)
	Palms and soles	1 (3.1%)
	Genitals	1 (3.1%)
Laboratory test
White blood cell count (27)^a	Elevated	24 (75.0%)
	Cells/mm^3	18100 (1000, 38100)^b
Neutrophil count (19)^a	Elevated	18 (56.3%)
	Cells/mm^3	14999 (8154.58, 30330)^b
Eosinophils (6)^a	Normal	6 (18.8%)
Erythrocyte sedimentation rate (6)^a	Elevated	3 (9.4%)
	Normal	3 (9.4%)
C-reactive protein (8)^a	Elevated	7 (21.9%)
	Normal	1 (3.1%)
Kidney function (12)^a	Acute kidney injury	2 (6.3%)
Liver function (11)^a	Acute liver injury	1 (3.1%)
Patch tests (5)^a	Negative	3 (9.4%)
	Positive	2 (6.3%)
Lymphocyte transformation test (3)^a	Negative	1 (3.1%)
	Positive	2 (6.3%)
Skin biopsy	Subcorneal pustule	21 (65.6%)
	Intraepidermal spongiform pustules	14 (43.8%)
	Necrotic keratinocytes	5 (15.6%)
	Spongy tissue hyperplasia	8 (25.0%)
	Exocytosis of neutrophils	11 (34.4%)
	Papillary dermal edema	13 (40.6%)
	Perivascular inflammatory infiltrates with neutrophils	1 (3.1%)
	Eosinophils	3 (9.4%)
	Lymphocytic	2 (6.3%)
	Mixed inflammatory infiltrate	14 (43.8%)

^arepresents the number of patients out of 32 on which information regarding this particular parameter was provided. ^bMedian (minimum-maximum).